Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 34Colorectal Neoplasms 26Lung Neoplasms 23Rectal Neoplasms 22Neoplasms 21Esophageal Squamous Cell Carcinoma 20Neoplasm Metastasis 19Esophageal Neoplasms 19Head and Neck Neoplasms 17Stomach Neoplasms 15Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Triple Negative Breast Neoplasms 12Small Cell Lung Carcinoma 12Ovarian Neoplasms 11Recurrence 10Nasopharyngeal Carcinoma 10Carcinoma, Squamous Cell 10Uterine Cervical Neoplasms 9Leukemia, Myeloid, Acute 9Colonic Neoplasms 9Glioblastoma 8Prostatic Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Melanoma 6Lymphoma, Non-Hodgkin 6

Interventions

Trastuzumab 12pyrotinib 8pertuzumab 5Docetaxel 5Paclitaxel 3trastuzumab deruxtecan 2Carboplatin 2Capecitabine 2tucatinib 1pegfilgrastim 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Protons 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Goserelin 1Fulvestrant 1Drug Therapy 1Cyclophosphamide 1Anastrozole 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2-positive Breast Cancer × Drug Therapy × Clear all
NCT04481932 2020-07-22

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Peking University

Phase 2 Recruiting
104 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡